Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants

Inclusion Criteria: * Age 18-75 years old- Patients with CD diagnosis confirmed by colonoscopy * Patients with inflammatory CD of terminal ileal, colonic or ileocolonic location * Maintenance treatment with at least 2 mg/kg/day for azathioprine/ 1 mg/kg/day for mercaptopurine or the highest dosage tolerated in patients who could not tolerate this dosage, at least 6 months. * Willingness to sign informed consent * If female of childbearing age, be post-menopausal, surgically sterile, or willing to use a reliable form of birth control for the duration of the study (such as physical barrier \[patient and partner\], contraceptive pill or patch, spermicide and barrier, or intrauterine device)and for at least five months after the last adalimumab treatment. * Able to comply with the requirements of the study. * CDAI score ≤ 220. * Calprotectin \> or = 250µg/g and/or hsCRP \> or = 5mg/L. * Significant lesions seen during colonoscopy, as defined by CDEIS. Exclusion Criteria: * Patients with an ostomy, or ileoanal pouch (subject with previous ileo-rectal anastomosis are not excluded), draining fistula, abscess * Patients who had intestinal resection within one year. * Symptomatic stricture either diagnosed by colonoscopy or clinically suspected and confirmed by imaging techniques. * Prior treatment with any anti-tumor necrosis factor (TNF) drug. * Patients receiving rectal treatment 1 month before inclusion * Signs of active infection * Previous history of active untreated or inade…